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Therapeutic immunization of HIV-1-infected individuals may induce and/or enhance HIV-1-specific immune responses and
decrease the dependency on antiretroviral drug treatment. However, repeated immunizations with live-recombinant vectors
may induce vector-specific immune responses that interfere with the elicitation of vigorous immune responses to the desired
antigen. Therefore, the use of mixed-modality vaccinations may be necessary to induce sustained virus-specific immune
responses in HIV-1-infected individuals treated with antiretroviral therapy (ART). Thus, the relative immunogenicity of various
vaccine modalities needs to be assessed. Here we compared the immunogenicity of two vaccine candidates, the canarypox-
based ALVAC-SIV-gag-pol-env (ALVAC-SIV-gpe) and the vaccinia-based NYVAC-SIV-gag-pol-env (NYVAC-SIV-gpe), in rhesus
macaques infected with SIVmac251 and treated with ART by 2 weeks postinfection. Both ALVAC-SIV-gpe and NYVAC-SIV-gpe
vaccine candidates induced and/or enhanced a virus-specific CD8 T cell response to a similar extent, as demonstrated by
tetramer staining of Gag-specific CD8 T cells. Similarly, both vaccines elicited comparable lymphoproliferative responsesINTRODUCTION
Despite the ability of highly active antiretroviral ther-
apy (HAART) to suppress the replication of HIV-1 and to
reduce the morbidity and mortality of HIV-1-infected in-
dividuals, the eradication of HIV-1 from its latent reser-
voirs seems unlikely (Chun et al., 1997; Wong et al., 1997).
The complexity of HAART regimens (Deeks et al., 1999)
and their side effects render long-term adherence diffi-
cult. Despite a partial reconstitution of immune compe-
tence during HAART in most HIV-1-infected individuals
(Autran et al., 1997; Landay et al., 2002; Lederman and
Valdez, 2000), virus-specific immune responses decline
during prolonged treatment (Casazza et al., 2001; Gray et
al., 1999; Kalams et al., 1999; Ogg et al., 1999; Pitcher et
al., 1999; Spiegel et al., 2000), presumably due to the
decreased exposure to viral antigens. Although suspen-
sion of antiretroviraltherapy (ART) results in an increase
in virus-specific immune responses in most patients,
viremia is usually not contained in the absence of HAART
(Davey et al., 1999; Ortiz et al., 1999). Since both CD4
and CD8 virus-specific T cell responses have been
associated with the containment of HIV replication (Koup
et al., 1994; Rosenberg et al., 1997), augmenting HIV-
specific immune responses by active vaccination before125HAART cessation may enhance HIV-specific immune re-
sponses and, hopefully, decrease the dependency on
drug treatment.
Repeated immunizations will most likely be needed to
induce and sustain strong virus-specific responses in
infected individuals. In fact, viremia containment in vac-
cinated ART-treated macaques with long-standing SIV-
mac251 infection after drug suspension is transient (E.
Tryniszewska et al., in press). However, repeated immu-
nizations even with replication-impaired recombinant
live vectors may induce sufficient vector-specific immune
responses to interfere with their ability to efficiently
present the desired antigens (Harrington et al., 2002;
Perkus et al., 1995; Yang et al., 1995). In addition, prior
vaccination with a live vector that failed to protect from
infection may preclude the use of the same live vector for
therapeutic vaccination in the same individual. Thus,
likely, several live-vector vaccine candidates will be
needed for immune therapy of HIV-1-infected individuals.
Therefore, it is important to assess the relative immuno-
genicity of several vaccine candidates in a nonhuman
primate model of HIV-1 infection of humans.
An effective therapeutic vaccine against HIV should
minimally replenish virus-specific CD4 T cell responses
and possibly elicit CD8 T cell responses of sufficient
breadth to prevent immune escape. The magnitude of
(LPRs) to the SIV p27 Gag and gp120 Env proteins. Thus,
suitable candidate vaccines for immune therapy of HIV-1-i
1 To whom correspondence and reprint requests should be ad-
dressed. Fax: 301-402-0055. E-mail: franchig@mail.nih.gov.
doi:10.1006/viro.2002.1722hese vaccine modalities alone or in combination may be
individuals. © 2002 Elsevier Science (USA)
virus-specific CD8 T cell responses and T helper re-
sponses has been inversely correlated with viremia con-
0042-6822/02 $35.00both t
nfected© 2002 Elsevier Science (USA)
All rights reserved.
tainment (Koup et al., 1994; Ogg et al., 1998; Rosenberg et
al., 1997). Similarly, in HIV-1-infected long-term nonpro-
gressors (LTNP) (Kalams et al., 1999; Kent et al., 1997;
Ogg et al., 1998; Rosenberg et al., 1997), these responses
are usually vigorous. Cell-mediated responses may also
protect from HIV infection in individuals at high risk of
infection (Mazzoli et al., 1997; Rowland-Jones and Mc-
Michael, 1995). Further evidence on the importance of
virus-specific CD8 T cell responses in the containment
of HIV/SIV infection is provided by the selection of im-
mune escape variants (Allen et al., 2000; Barouch et al.,
2002; Borrow et al., 1994; Evans et al., 1999; Koenig et al.,
1995; Price et al., 1997) (J. Nacsa et al., in press), by the
temporary decrease of plasma virus levels following
transfusion of autologous HIV Gag-specific CD8 cyto-
toxic T lymphocyte (CTL) clones to HIV-1-infected indi-
viduals (Brodie et al., 1999), and by the increase of
plasma virus levels in rhesus macaques infected with
SIVmac251 following depletion of CD8 T cells (Jin et al.,
1999; Matano et al., 1998; Schmitz et al., 1999). Contain-
ment of viral rebound following the suspension of ART in
primary HIV-1 infection of humans (Rosenberg et al.,
2000) or SIV infection of macaques (Hel et al., 2000;
Lifson et al., 2000, 2001) was shown to correlate with
both virus-specific CD4 (Hel et al., 2000) and CD8 T
cell responses (Lifson et al., 2001).
The highly attenuated vaccinia-based vector NYVAC-
SIV-gpe (Benson et al., 1998) is able to induce and
expand SIV-specific CD4 and CD8 T cell responses in
SIVmac251-infected rhesus macaques treated with ART
during primary infection (Hel et al., 2000). In addition, the
same vaccine used to immunize macaques treated with
ART during long-standing SIVmac251 infection signifi-
cantly ameliorated the virological outcome following ART
withdrawal (E. Tryniszewska et al., in press). Herein we
aimed to assess the immunogenicity of a canarypox-
based ALVAC-SIV-gpe vaccine candidate (Pal et al.,
2002) in SIVmac251-infected rhesus macaques treated
during primary infection with ART and compare it to the
immunogenicity of the NYVAC-SIV-gpe vaccine candi-
date.
RESULTS AND DISCUSSION
A total of 19 naive rhesus macaques were infected
intravenously with ten 50% tissue culture infectious
doses (TCID50) of the highly pathogenic SIVmac251 (561)
(Pal et al., 2002). All macaques became infected, as
evidenced by high plasma viral load at week 2 postchal-
lenge (Fig. 1). Starting at day 15, all macaques were
treated with ART as described (Hel et al., 2000). Follow-
ing the initiation of ART, a rapid decrease of plasma virus
levels was observed and in most macaques viral RNA in
plasma was undetectable (2000 copies) by week 6
from treatment and thereafter (Fig. 1). Macaques in
group A were immunized three times (weeks 10, 19, and
23) intramuscularly with 108 PFU of the mock ALVAC
vaccine. The macaques in group B were immunized with
the ALVAC-SIV-gpe vaccine candidate at the same time
as macaques in group A. In contrast, macaques in group
C were immunized only twice (weeks 10 and 19) with 108
PFU of NYVAC-SIV-gpe. Therefore, comparison of the
immunogenicity of these vaccine modalities will span
only the first 21-week interval.
Most of the animals in group A spontaneously devel-
oped lymphoproliferative responses (LPRs) specific to
the p27 Gag antigen following ART treatment (Fig. 2a), as
expected (Hel et al., 2000). A similar finding has been
reported in HIV-1-infected individuals treated with ART
during primary infection (Rosenberg et al., 2000). In con-
trast, low to undetectable levels of LPRs specific to the
gp120 Env antigen were observed in the macaques from
group A (Fig. 2d). The immunizations of group B animals
with ALVAC-SIV-gpe resulted in the induction of both p27
Gag- and gp120 Env-specific LPRs (Figs. 2b and 2e) in
several macaques. While the gp120 Env LPRs were sig-
nificantly higher in the ALVAC-SIV-gpe-vaccinated group
B animals compared to the control group A throughout
the vaccination period (P  0.0005, weeks 11 to 26,
analyzed by repeated measures ANOVA (RM ANOVA)); in
the case of the p27 Gag-specific LPRs, no significant
differences were observed between group A and group
B macaques. Similarly, two immunizations with the NY-
VAC-SIV-gpe vaccine of group C animals induced signif-
icantly higher LPRs to gp120 Env (P  106, weeks
11–21) but, in the case of p27 Gag, LPRs only ap-
proached statistical significance (P  0.07) when com-
pared to control group A (Figs. 2c and 2f). At the individ-
ual level, variability in the ability to respond to the vac-
cines was observed in both group B and group C
macaques as in the case of macaque 769 that failed to
mount responses to both p27 Gag and gp120.
To quantitate the vaccine-induced T cell responses,
we measured the frequency of CD3CD8 T cells spe-
cific to the Mamu-A*01-restricted immunodominant
epitope Gag181–189 CM9 (Kuroda et al., 1998) in the Mamu-
A*01-positive macaques included in the groups (Fig. 3).
Vaccination of group B animals with ALVAC-SIV-gpe in-
duced high frequencies of Gag181–189 CM9-specific T cells
in a range from 2.5 to 11.2% of the total CD3CD8 T cell
population (Fig. 3b). In contrast, the frequencies of
Gag181–189 CM9-specific cells in the blood of the mock-
vaccinated macaques in group A were significantly lower
(P  0.007, weeks 11–26, RM ANOVA) and remained
below 2% throughout the vaccination period (Fig. 3a).
Similarly, immunization of group C animals with NYVAC-
SIV-gpe induced high numbers of Gag181–189 CM9-specific
T cells in both the Mamu-A*01-positive macaques 689
and 690 (up to 8% of the total CD3CD8 T cell popula-
tion).
Last, we compared the extent of virus-specific immune
responses elicited by the NYVAC-SIV-gpe and ALVAC-
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SIV-gpe vaccine candidates during the interval between
weeks 10 and 21 (Fig. 4). The p27 Gag LPRs and gp120
LPRs induced by the ALVAC-SIV-gpe vaccine candidate
were not significantly different from those induced by
NYVAC-SIV-gpe (P  0.89, P  0.1, respectively; RM
ANOVA). The overall frequency of the CD3CD8 T cells
staining the Gag181–189 CM9 tetramer did not differ (Fig. 4c)
in the Mamu-A*01-positive macaques from groups B and
FIG. 1. Viral load in SIVmac251-infected rhesus macaques. (a, b, and c) Rhesus macaques were infected intravenously with SIVmac251 (561) (Pal
et al., 2002) (day 0) and treatment with ART was initiated at day 15 from infection. At weeks 10, 19, and 23, the macaques were immunized
intramuscularly with either mock ALVAC (group A) or the ALVAC-SIV-gpe vaccine candidate (group B). The animals in group C were inoculated with
the NYVAC-SIV-gpe vaccine candidate at weeks 10 and 19.
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FIG. 2. ALVAC-SIV-gpe and NYVAC-SIV-gpe vaccine candidates induced SIV-specific LPRs in SIVmac251-infected macaques. Mean LPRs calculated
as S.I.s to the p27 Gag (a, b, and c) and gp120 Env (d, e, and f) antigens were determined as previously described (Hel et al., 2000).
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FIG. 2—Continued
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C, although the kinetics of induction of the response
appeared to be faster in macaques immunized with NY-
VAC-SIV-gpe.
Thus, the immunogenicity of the canarypox-based AL-
VAC-SIV-gpe and of the highly attenuated poxvirus-based
NYVAC-SIV-gpe vaccine candidates in SIVmac251-in-
fected ART-treated macaques does not appear to differ
significantly.
In this study, the ALVAC-SIV-gpe vaccine candidate
elicited substantial CD4 and CD8 T cell responses. A
study with an equivalent canarypox-based HIV-1 vaccine
in HIV-1-infected individuals also elicited both CD4 and
FIG. 3. ALVAC-SIV-gpe and NYVAC-SIV-gpe vaccine candidates increased the frequency of Gag181–189 CM9-specific CD3
CD8 T cells in the blood
of SIVmac251-infected macaques. The percentage of cells staining with the Mamu-A*01-restricted Gag181–189 CM9-specific tetrameric complex out of
the total CD3CD8 T cell population in fresh PBMCs was determined in Mamu-A*01-positive macaques, as previously described (Hel et al., 2000).
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CD8 HIV-specific immune responses (Jin et al., 2002).
However, in that study lower doses of the recombinant
ALVAC HIV-1 vaccine were used and only a transient
virological benefit was observed in some patients
(Markowitz et al., 2002). Here we demonstrate that both
the canarypox-based ALVAC and the poxvirus-based NY-
VAC at 108 PFU per inoculation were highly immuno-
genic. The relative efficacy of immunization could not be
assessed in the studies reported here since ART treat-
ment alone during primary infection results in viremia
control following ART suspension in 80% of macaques
(G. Franchini, in press; J. Nacsa et al., in press). In
addition to being safe (Hel et al., 2000; Jin et al., 2002),
these two vectors display limited, if any, immune cross-
reactivity with each other (Clements-Mann et al., 1998). In
fact, vaccination with recombinant ALVAC-SIV-gpe of
monkeys previously immunized with NYVAC-SIV-gpe did
not preclude a further enhancement of SIV-specific im-
mune responses and, importantly, appeared to amelio-
rate the virological outcome following ART cessation (Y.
FIG. 4. ALVAC-SIV-gpe and NYVAC-SIV-gpe vaccine candidates induced similar levels of virus-specific immune responses. Mean values of SIs for
the p27 Gag (a) and gp120 Env (b) and the frequency of ex vivo Gag181–189 CM9 tetramer-staining CD3
CD8 T cells in the blood of the immunized
macaques are shown over time.
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Edghill-Smith et al., unpublished data). Thus, it could be
envisioned that both vaccine modalities at the dose
tested here or at higher doses could be used in sequen-
tial immunization regimens of HIV-1-infected individuals.
MATERIALS AND METHODS
Animals, immunizations, and ART therapy
All animals were colony-bred Indian rhesus macaques
(Macaca mulatta) obtained from Covance Research
Products (Alice, TX). The animals were housed and han-
dled in accordance with the standards of the Association
for the Assessment and Accreditation of Laboratory An-
imal Care International (AAALAC International). All rhe-
sus macaques were seronegative for simian retrovirus
(SRV), STLV-1, and herpesvirus B prior to the study. The
macaques were screened by PCR and sequencing for
the presence of the Mamu-A*01 allele as described (Hel
et al., 2001).
All rhesus macaques were infected intravenously with
10 TCID50 of the highly pathogenic SIVmac251 (561) (Pal
et al., 2002). The challenge virus stock was prepared
from phytohemoaglutinin (PHA)-activated PBMC ob-
tained from Mamu-A*01-positive macaque 561L previ-
ously inoculated vaginally with SIVmac251. SIVmac251
RNA in plasma was quantitated by nucleic acid se-
quence-based amplification (Romano et al., 1997). The
detection limit of this assay is 2 103 RNA copies/100 l
of plasma.
Starting at day 15, all macaques were treated with ART
consisting of 20 mg/kg/day of (R)-9-(2-phosphonyl-
methoypropyl)adenine (PMPA) administered subcutane-
ously (Tsai et al., 1995), 2.4 mg/kg/day of Stavudine (d4T)
divided into two daily doses administered orally, and 10
mg/kg/day of didanosine (DDI) administered intrave-
nously, as described (Hel et al., 2000). The animals were
immunized im with 108 PFU of mock ALVAC (group A),
ALVAC-SIV-gag, pol, env (group B), or NYVAC-SIV-gag,
pol, env (group C) at times indicated.
Lymphocyte proliferation assay
The Ficoll-purified PBMC were resuspended in RPMI-
1640 medium (Gibco-BRL, Gaithersburg, MD) containing
5% inactivated human A/B serum and antibiotics (Sigma,
St. Louis, MO) and cultured at 105 cells per well in
triplicate for 3 days in an absence or presence of native
HPLC-purified SIVmac Gag p27 or Env gp120 proteins
(Advanced BioScience Laboratories, Rockville, MD) or
Concanavalin A as a positive control. The cells were then
pulsed overnight with 1 Ci of [3H]thymidine prior to
harvest. The relative rate of lymphoproliferation was cal-
culated as fold of thymidine incorporation into cellular
DNA over medium control (SI).
Detection of epitope-specific CD3CD8 T
lymphocytes by tetramer staining
Fresh PBMC were stained with anti-human CD3 Ab
(PerCP labeled, clone SP34, Pharmingen, San Diego,
CA), anti-human CD8 Ab (FITC-labeled, Becton-Dickin-
son, San Jose, CA), and Mamu-A*01 tetrameric com-
plexes refolded in the presence of a specific peptide and
conjugated to PE-labeled streptavidin (Molecular Probes,
Eugene, OR). Gag181–189 CM9 (CTPYDINQM) (Gag_CM9)-
and Tat28–35SL8 (TTPESANL) (Tat_SL8)-specific tetramers
were used. Samples were analyzed on FACSCalibur
(Becton–Dickinson) and the data are presented as per-
centage of tetramer-positive cells out of all CD3CD8
lymphocytes.
Statistical analysis
All reported P values are two-sided. RM ANOVA anal-
ysis was performed on transformed data as described
(Hel et al., 2000). The NCSS (Kaysville, UT) and Sigmastat
(version 2.0, SPSS, Chicago, IL) statistical software pack-
ages were used for the analyses.
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